Christopher van der Walle

After 14 years in academia researching dosage form design, Chris van der Walle moved to the biopharmaceutical industry, first developing formulations for monoclonal antibodies in MedImmune and then mRNA-lipid nanoparticles in AstraZeneca. He led the formulation team in GlaxoSmithKline developing CAR-T cell therapies, and the Cell & Gene Therapy Catapult’s Edinburgh facility, working on induced pluripotent stem cell stems. He is currently Head of Formulation Science at the MHRA, producing pilot batches of biological reference materials.